• Muh. Irham Bakhtiar Universitas Muhammadiyah Kalimantan Timur
  • Chera Ananda Mukti Universitas Muhammadiyah kalimantan Timur
Keywords: Therapeutic Rationality, Peptic Ulcer, Inpatient


Peptic ulcer is one of the most common gastrointestinal diseases and affects almost 10% of the world's population. Ideally peptic ulcer treatment should be highly effective, free of significant side effects, easy to comply with, and cost effective. This study aims to determine the treatment profile of peptic ulcer patients at the inpatient installation of RS X Kota Samarinda and to determine the rationality of treatment for ulcer patients at the inpatient installation of RS X Kota Samarinda. The research was conducted using a retrospective method. Data collection in this study used a purposive sampling technique in accordance with the inclusion and exclusion criteria and obtained 37 samples of medical record data. Based on the results of the study, it was found that the results of the treatment profile in peptic ulcer patients, the most widely used type of therapy was a combination of PPI (proton pump inhibitor) + cytoprotective (mucosal protector) of 54.1% and a combination of PPI (proton pump inhibitor) + antibiotics + cytoprotective of 54.1%. 10.8%. The most widely used drugs were omeprazole (37.9%), sucralfate (27.5%), lansoprazole (6.9%), amoxicillin (6.9%), clarithromycin (6.7%), pantoprazole (5, 7%), ranitidine (5.6%), rebamipide (2.2%), and metronidazole (1.1%). Rationality in peptic ulcer patients on the use of antibiotics with the Gyssens method obtained category 0 in 5 patients (83.3%) and category IVA in 1 patient (16.7%). Rationality in peptic ulcer patients on the use of gastric acid controlling drugs was found to be 97.3% correct indication, 62.2% correct dose, 100% correct duration.


Almeida, N., Romaozinho, J. M., Donato, M. M., Luxo, C., Cardoso, O., Cipriano, M. A., . . . Sofia, C. J. H. (2014). Triple Therapy with High‐Dose Proton‐Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for H elicobacter pylori Eradication: A Proof‐of‐Concept Study. 19(2), 90-97.

Banerjee, S., Cash, B. D., Dominitz, J. A., Baron, T. H., Anderson, M. A., Ben-Menachem, T., . . . Ikenberry, S. O. J. G. e. (2010). The role of endoscopy in the management of patients with peptic ulcer disease. 71(4), 663-668.

Chey, D, W., Leontiadis, I, G., Howden, W, C., . . . F, S. (2017). ACG clinical guideline: treatment of Helicobacter pylori infection. 112(2), 212-239.

Chisholm-Burns, M. A., Terry L. Schwinghammer, Patrick M. Malone, Jill M. Kolesar, P. Brandon Bookstaver, & Lee, K. C. (2022). Pharmacotherapy Principles & Practice (Edition 6th ed.): McGraw Hill.

Dinkes. (2018). Profil Kesehatan Kota Samarinda. In. Samarinda: Dinas Kesehatan.

DiPiro, T., J., C., Y. G., L., P., T., M. H. S., D., N. T., & L., E. V. (2020). Pharmacotherapy : a pathophysiologic approach.

DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. (2017). Pharmacotherapy A Pathophysiologic Approach, 10e. 255-258.

Gargallo, J, C., Sostres, Carlos, Lanas, & Angel. (2014). Prevention and treatment of NSAID gastropathy. 12(4), 398-413.

Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J., & Loscalzo, J. (2015). Harrison's principles of internal medicine, 19e (Vol. 1): Mcgraw-hill New York, NY, USA:.

Kyle, A, R., Steensma, P, D., Shampo, & A, M. (2016). Barry James Marshall—Discovery of Helicobacter pylori as a cause of peptic ulcer. Paper presented at the Mayo Clinic Proceedings.

Love, B. L., & Mohorn, P. L. (2020). Peptic Ulcer Disease and Related Disorders. In J. T. DiPiro, G. C. Yee, L. M. Posey, S. T. Haines, T. D. Nolin, & V. Ellingrod (Eds.), Pharmacotherapy: A Pathophysiologic Approach, 11e. New York, NY: McGraw-Hill Education.

Melcarne, Luigi, García-Iglesias, Pilar, Calvet, & Xavier. (2016). Management of NSAID-associated peptic ulcer disease. 10(6), 723-733.

Peery, A., Crockett, S., Barritt, A., Dellon, E., Eluri, S. J. B. o. g., liver,, & Gastroenterology, p. d. i. t. U. S. (2015). Gangarosa LMet al. 149, 1731-1741.

Recta, O. U. F. A., Vera Fitriya Ersalena. (2022). Evaluasi Kesesuaian Regimen Terapi Obat Ulkus Peptikum Di Instalasi Rawat Inap RSUD Provinsi Nusa Tenggara Barat. Jurnal Ilmiah Farmasi, 11 No. 1.

Sverdén, Emma, Agréus, Lars, Dunn, M, J., . . . Jesper. (2019). Peptic ulcer disease. 367.

Venkateswararao, Chitta, & Venkataramana. (2013). A pharmacological review on natural antiulcer agents. 4, 1118-1131.

Whalen, K. (2018). Lippincott® Illustrated Reviews: Pharmacology: Wolters kluwer india Pvt Ltd.

WHO. (2020). World Health Statistics. World Health Organization.